Our Blog | Biosimilars & Generics | AAM

COVID-19 and AAM - FAQ's and resources from the U.S. generics and biosimilars industry.

Protective Mask - COVID-19

Mar 30, 2020 | Jeff Francer

COVID-19: This Week’s Initiatives From the Generic and Biosimilars Industry

COVID-19 Response - Patient Access to Medicines

Mar 19, 2020 | Jeff Francer

AAM’s COVID-19 Response: Helping Patients and Families Meet Their Health Care Needs

Mar 18, 2020 | Joseph Stewart

Top 10 Ways to Commemorate the 10th Anniversary of Biosimilars in the U.S.

Coronavirus

Feb 28, 2020 | Jeff Francer

AAM Interim CEO Jeff Francer on COVID-19

Feb 28, 2020 | Erica Klinger

Stories and Data: How AAM Equips Advocates in the States

Feb 27, 2020 | Erik Komendant

The First (Price) Cut Is the Steepest

Feb 25, 2020 | Sara Skubikowski

Savings by Condition: The Latest Data

Jan 9, 2020 | Karin Hessler

Competition Matters. That’s Why We Need to Further Improve IPR.

Dec 18, 2019 | Kristin Murphy

Women-Powered Health Policy: 500 and Counting

Nov 19, 2019 | Jonathan Kimball

Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA

Nov 18, 2019 | Erica Klinger

Dispensary of Hope: The Industry’s Nonprofit Supply-Chain Partner

Nov 14, 2019 | Erica Klinger

How Our Associate Members Make the World Healthier